How MS treatment “burden” may affect taking medicines
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at whether the amount of MS treatment-related “burden” in the mouth and body affects how well people stick to their disease-modifying therapy. It may help doctors understand which patients are more likely to have trouble following treatment after switching or starting certain MS medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a confirmed diagnosis of multiple sclerosis (MS).
- Within the last 2 months, you started or switched to one of these MS medicines: cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, or diroximel fumarate.
- You can read and write in English.
- You have internet and a computer (or device) to complete the study assessments.
- You are not taking any other MS disease-modifying therapy besides the listed medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how switching or failing multiple sclerosis (MS) treatments affects your feelings and daily life. It may help doctors better support people with relapsing-remitting MS.
This study looks at how taking teriflunomide (an oral medication) affects tiredness and daily activities in people with relapsing multiple sclerosis. It will follow you for a year, checking your energy levels and physical function through simple tests and questionnaires.
This study helps people with MS understand their medications better by having a healthcare person visit your home to review what you're taking and how you're using it. The goal is to make sure you're getting the most benefit from your medicines.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This study tests whether cladribine tablets can help people with stable, long-standing RRMS safely stop their current disease-modifying therapy. It may be an option if your MS has been quiet for years and you want to consider a treatment break.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.